Skip to main content
Erschienen in: Seminars in Immunopathology 1/2019

02.07.2018 | Review

The T-win® technology: immune-modulating vaccines

verfasst von: Mads Hald Andersen

Erschienen in: Seminars in Immunopathology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The T-win® technology is an innovative investigational approach designed to activate the body’s endogenous anti-regulatory T cells (anti-Tregs) to target regulatory as well as malignant cells. Anti-Tregs are naturally occurring T cells that can directly react against regulatory immune cells because they recognize proteins that these targets express, including indoleamine 2,3-dioxygenase (IDO), tryptophan 2,6-dioxygenase, arginase, and programmed death ligand 1 (PD-L1). The T-win® technology is characterized by therapeutic vaccination with long peptide epitopes derived from these antigens and therefore offers a novel way to target genetically stable cells with regular human leukocyte antigen expression in the tumor microenvironment. The T-win® technology thus also represents a novel way to attract pro-inflammatory cells to the tumor microenvironment where they can directly affect immune inhibitory pathways, potentially altering tolerance to tumor antigens. The modification of an immune regulatory environment into a pro-inflammatory milieu potentiates effective anti-tumor T cell responses. Many regulatory immune cells may be reverted into effector cells given the right stimulus. Because T-win® technology is based on the immune-modulatory function of the vaccines, the vaccines activate both CD4 and CD8 anti-Tregs. Of importance, in clinical trials, vaccinations against IDO or PD-L1 to potentiate anti-Tregs have so far proved to be safe, with minimal toxicity.
Literatur
1.
Zurück zum Zitat Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D (2007) Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol 171(6):1936–1943CrossRefPubMedPubMedCentral Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D (2007) Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol 171(6):1936–1943CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Popov A, Schultze JL (2008) IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 86(2):145–160CrossRefPubMed Popov A, Schultze JL (2008) IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 86(2):145–160CrossRefPubMed
3.
Zurück zum Zitat Gianchecchi E, Delfino DV, Fierabracci A (2013) Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 12(11):1091–1100CrossRefPubMed Gianchecchi E, Delfino DV, Fierabracci A (2013) Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 12(11):1091–1100CrossRefPubMed
5.
Zurück zum Zitat Andersen MH (2015) Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst 107(9):154CrossRef Andersen MH (2015) Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst 107(9):154CrossRef
6.
Zurück zum Zitat Yu W, Jiang N, Ebert PJ, Kidd BA, Muller S, Lund PJ et al (2015) Clonal deletion prunes but does not eliminate self-specific alphabeta CD8(+) T lymphocytes. Immunity 42(5):929–941CrossRefPubMedPubMedCentral Yu W, Jiang N, Ebert PJ, Kidd BA, Muller S, Lund PJ et al (2015) Clonal deletion prunes but does not eliminate self-specific alphabeta CD8(+) T lymphocytes. Immunity 42(5):929–941CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, thor Straten P, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200–2210CrossRefPubMedPubMedCentral Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, thor Straten P, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200–2210CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN et al (2009) The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 4(9):e6910CrossRefPubMedPubMedCentral Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN et al (2009) The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 4(9):e6910CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK et al (2013) HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 73(6):1674–1776CrossRef Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK et al (2013) HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 73(6):1674–1776CrossRef
10.
Zurück zum Zitat Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH (2013) Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27(11):2251–2253CrossRefPubMed Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH (2013) Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27(11):2251–2253CrossRefPubMed
11.
Zurück zum Zitat Larsen SK, Munir S, Woetmann A, Froesig TM, Odum N, Svane IM et al (2013) Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia 27(12):2332–2340CrossRefPubMed Larsen SK, Munir S, Woetmann A, Froesig TM, Odum N, Svane IM et al (2013) Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia 27(12):2332–2340CrossRefPubMed
12.
Zurück zum Zitat Martinenaite E, Ahmad SM, Hansen M, Met O, Westergaard MW, Larsen SK et al (2016) CCL22-specific T cells: modulating the immunosuppressive tumor microenvironment. Oncoimmunology 5(11):e1238541CrossRefPubMedPubMedCentral Martinenaite E, Ahmad SM, Hansen M, Met O, Westergaard MW, Larsen SK et al (2016) CCL22-specific T cells: modulating the immunosuppressive tumor microenvironment. Oncoimmunology 5(11):e1238541CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Hjortso MC, Larsen SK, Kongsted P, Met O, Frosig TM, Andersen GH et al (2015) Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology 4(1):e968480CrossRefPubMedPubMedCentral Hjortso MC, Larsen SK, Kongsted P, Met O, Frosig TM, Andersen GH et al (2015) Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology 4(1):e968480CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Andersen MH (2018) The balance players of the adaptive immune system. Cancer Res 78(6):1379–1382CrossRefPubMed Andersen MH (2018) The balance players of the adaptive immune system. Cancer Res 78(6):1379–1382CrossRefPubMed
17.
Zurück zum Zitat Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J et al (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst 109(4):2982600CrossRef Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J et al (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst 109(4):2982600CrossRef
18.
Zurück zum Zitat Prendergast GC, Metz R, Muller AJ (2009) IDO recruits Tregs in melanoma. Cell Cycle 8(12):1818–1819CrossRefPubMed Prendergast GC, Metz R, Muller AJ (2009) IDO recruits Tregs in melanoma. Cell Cycle 8(12):1818–1819CrossRefPubMed
19.
Zurück zum Zitat Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17):3520–3530CrossRefPubMed Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17):3520–3530CrossRefPubMed
20.
Zurück zum Zitat Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8):722–735CrossRefPubMedPubMedCentral Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8):722–735CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Mullard A (2018) IDO takes a blow. Nat Rev Drug Discov 17(5):307PubMed Mullard A (2018) IDO takes a blow. Nat Rev Drug Discov 17(5):307PubMed
23.
Zurück zum Zitat Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J et al (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from Indoleamine 2,3 dioxygenase. Clin Cancer Res 20(1):221–232CrossRefPubMed Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J et al (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from Indoleamine 2,3 dioxygenase. Clin Cancer Res 20(1):221–232CrossRefPubMed
24.
Zurück zum Zitat Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T, Ichiki Y, Yasuda M, So T, Takenoyama M, Sugio K, Nagashima A, Yasumoto K (2009) Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 65(1):91–97CrossRefPubMed Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T, Ichiki Y, Yasuda M, So T, Takenoyama M, Sugio K, Nagashima A, Yasumoto K (2009) Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 65(1):91–97CrossRefPubMed
25.
Zurück zum Zitat Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM (2016) Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 18(8):1043–1055CrossRefPubMed Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM (2016) Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 18(8):1043–1055CrossRefPubMed
26.
Zurück zum Zitat Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, de Plaen E, Uyttenhove C, Wouters J, Masereel B, van den Eynde BJ (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 109(7):2497–2502CrossRefPubMedPubMedCentral Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, de Plaen E, Uyttenhove C, Wouters J, Masereel B, van den Eynde BJ (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 109(7):2497–2502CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197–203CrossRefPubMed Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197–203CrossRefPubMed
28.
Zurück zum Zitat Yu CP, Song YL, Zhu ZM, Huang B, Xiao YQ, Luo DY (2017) Targeting TDO in cancer immunotherapy. Med Oncol 34(5):73–0933CrossRefPubMed Yu CP, Song YL, Zhu ZM, Huang B, Xiao YQ, Luo DY (2017) Targeting TDO in cancer immunotherapy. Med Oncol 34(5):73–0933CrossRefPubMed
29.
Zurück zum Zitat Hsu YL, Hung JY, Chiang SY, Jian SF, Wu CY, Lin YS, Tsai YM, Chou SH, Tsai MJ, Kuo PL (2016) Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 7(19):27584–27598CrossRefPubMedPubMedCentral Hsu YL, Hung JY, Chiang SY, Jian SF, Wu CY, Lin YS, Tsai YM, Chou SH, Tsai MJ, Kuo PL (2016) Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 7(19):27584–27598CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten P, Andersen MH (2012) Natural CD4(+) T-cell responses against Indoleamine 2,3-dioxygenase. PLoS One 7(4):e34568CrossRefPubMedPubMedCentral Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten P, Andersen MH (2012) Natural CD4(+) T-cell responses against Indoleamine 2,3-dioxygenase. PLoS One 7(4):e34568CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Chen Z, O'Shea JJ (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol Res 41(2):87–102CrossRefPubMed Chen Z, O'Shea JJ (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol Res 41(2):87–102CrossRefPubMed
34.
Zurück zum Zitat Sundrud MS, Trivigno C (2013) Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 25(4):263–272CrossRefPubMed Sundrud MS, Trivigno C (2013) Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 25(4):263–272CrossRefPubMed
35.
Zurück zum Zitat Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548CrossRefPubMedPubMedCentral Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548CrossRefPubMedPubMedCentral
36.
37.
Zurück zum Zitat Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM et al (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 5(4):e1000371CrossRefPubMedPubMedCentral Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM et al (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 5(4):e1000371CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N (2009) PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23(2):375–382CrossRefPubMed Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N (2009) PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23(2):375–382CrossRefPubMed
40.
Zurück zum Zitat Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280–1288CrossRefPubMed Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280–1288CrossRefPubMed
41.
Zurück zum Zitat Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 26(3):424–432CrossRefPubMed Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 26(3):424–432CrossRefPubMed
42.
Zurück zum Zitat Kollgaard T, Petersen SL, Hadrup SR, Masmas TN, Seremet T, Andersen MH, Madsen HO, Vindeløv L, thor Straten P (2005) Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 19(12):2273–2280CrossRefPubMed Kollgaard T, Petersen SL, Hadrup SR, Masmas TN, Seremet T, Andersen MH, Madsen HO, Vindeløv L, thor Straten P (2005) Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 19(12):2273–2280CrossRefPubMed
43.
Zurück zum Zitat Ame-Thomas P, Le PJ, Yssel H, Caron G, Pangault C, Jean R et al (2012) Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26(5):1053–1063CrossRefPubMed Ame-Thomas P, Le PJ, Yssel H, Caron G, Pangault C, Jean R et al (2012) Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26(5):1053–1063CrossRefPubMed
44.
Zurück zum Zitat van de Donk NW, Kamps S, Mutis T, Lokhorst HM (2012) Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 26(2):199–213CrossRefPubMed van de Donk NW, Kamps S, Mutis T, Lokhorst HM (2012) Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 26(2):199–213CrossRefPubMed
45.
Zurück zum Zitat Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K (2013) Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27(2):464–472CrossRefPubMed Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K (2013) Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27(2):464–472CrossRefPubMed
47.
Zurück zum Zitat Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465CrossRefPubMedPubMedCentral Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2453CrossRefPubMedPubMedCentral Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2453CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Munir S, Andersen GH, Svane IM, Andersen MH (2013) The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2(4):e23991CrossRefPubMedPubMedCentral Munir S, Andersen GH, Svane IM, Andersen MH (2013) The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2(4):e23991CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Ahmad SM, Larsen SK, Svane IM, Andersen MH (2014) Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28(1):236–238CrossRefPubMed Ahmad SM, Larsen SK, Svane IM, Andersen MH (2014) Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28(1):236–238CrossRefPubMed
51.
Zurück zum Zitat Minami T, Minami T, Shimizu N, Yamamoto Y, De VM, Nozawa M et al (2015) Identification of programmed death ligand 1-derived peptides capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. J Immunother 38(7):285–291CrossRefPubMed Minami T, Minami T, Shimizu N, Yamamoto Y, De VM, Nozawa M et al (2015) Identification of programmed death ligand 1-derived peptides capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. J Immunother 38(7):285–291CrossRefPubMed
52.
Zurück zum Zitat Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CLW, Chen L (2003) Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111(3):363–370CrossRefPubMedPubMedCentral Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CLW, Chen L (2003) Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111(3):363–370CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949CrossRefPubMed Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949CrossRefPubMed
54.
Zurück zum Zitat Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66(11):5716–5722CrossRefPubMed Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66(11):5716–5722CrossRefPubMed
55.
Zurück zum Zitat Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Menetrier-Caux C (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69(5):2000–2009CrossRefPubMed Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Menetrier-Caux C (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69(5):2000–2009CrossRefPubMed
57.
Zurück zum Zitat Ahmad SM, Martinenaite E, Hansen M, Junker N, Borch TH, Met O et al (2016) PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 5(8):e1202391CrossRef Ahmad SM, Martinenaite E, Hansen M, Junker N, Borch TH, Met O et al (2016) PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 5(8):e1202391CrossRef
Metadaten
Titel
The T-win® technology: immune-modulating vaccines
verfasst von
Mads Hald Andersen
Publikationsdatum
02.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Seminars in Immunopathology / Ausgabe 1/2019
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-018-0695-8

Weitere Artikel der Ausgabe 1/2019

Seminars in Immunopathology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.